Pfizer
Search results
Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.
For more than a decade, Bristol Myers Squibb has been providing medicines to patients in India, and we are excited to be expanding our operations to Hyderabad in 2023. At BMS Hyderabad, we are dedicated to paving the way towards a brighter future and a better world.
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations.
Learn more about Bristol Myers Squibb and our mission to discover, develop and deliver innovative medicines to patients with serious diseases.
We promote health equity and seek to improve the health outcomes of populations disproportionately affected by serious diseases. Learn about global biopharmaceutical innovator Bristol Myers Squibb, helping millions to fight cancer, cardiovascular disease, HIV/AIDS, and more.
1 day ago · Bristol Myers Squibb’s adjusted gross margin declined by 230 bps y-o-y to 77.8% in Q1’24, partly due to product mix. Bristol Myers Squibb recorded a one-time charge of $12.1 billion for the ...
Jun 21, 2024 · Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
Feb 2, 2023 · Bristol Myers Squibb posted revenues of $11.4 billion, a decrease of 5%, driven by recent LOE products (primarily Revlimid) and foreign exchange impacts, partially offset by in-line products (primarily Opdivo) and our new product portfolio (primarily Opdualag and Abecma ). When adjusted for foreign exchange, revenues decreased 1%.
Feb 4, 2022 · Bristol Myers Squibb posted fourth quarter revenues of $12.0 billion, an increase of 8%, driven by Eliquis, our Immuno-Oncology and new product portfolios. U.S. revenues increased 11% to $7.5 billion in the quarter.
Discover what it means to have a meaningful career. At Bristol Myers Squibb, you'll transform patients' lives and help them prevail over serious diseases.
